UT Southwestern physicians to test oral insulin to prevent type I diabetes

September 10, 1996

DALLAS, Texas, September 10, 1996 -- UT Southwestern Medical Center at Dallas physicians will soon begin testing a new oral insulin capsule to determine if it can prevent or delay insulin-dependent diabetes mellitus, or type I diabetes, as part of a nationwide clinical study sponsored by the National Institutes of Health (NIH).

The oral insulin intervention study is the second phase of the Diabetes Prevention Trial -- Type I (DPT-1) sponsored by the NIH's National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). It is designed for people at moderate risk for developing type I diabetes, also known as juvenile-onset diabetes. Phase one, using insulin injections for intervention, was launched in February 1994 and is designed for those at high risk for developing type I diabetes.

For the study UT Southwestern, the only medical center in Texas participating, is recruiting persons between the ages of 3 and 45 who have relatives with type I diabetes. Once enrolled, those at moderate risk -- having a 25 percent to 50 percent chance of developing the disease in five years -- will take one insulin capsule a day. Those at high risk will administer two insulin injections a day.

"Each year, more than 500 new cases of type I diabetes are diagnosed in our community; 120 to 140 of these are at Children's Medical Center, the pediatric teaching hospital for UT Southwestern physicians," said Dr. Philip Raskin, UT Southwestern professor of internal medicine and principal investigator of DPT-1 at UT Southwestern. "Another 17,500 people in the metropolitan area are at risk for developing the disease.

"Through the DPT-1, we hope to find that an insulin capsule or low doses of insulin by injection may prevent or delay diabetes."

Type I diabetics produce very little or no insulin, a hormone that regulates how cells use and store energy from food. It is believed that white blood cells vital to the body's defense against infectious diseases launch a self-directed, or autoimmune, attack on the insulin-producing beta cells in the pancreas. As a result, blood glucose builds to dangerous levels, causing damage to the eyes, kidneys, nerves and heart. Without daily insulin injections, people with type I diabetes will lapse into a coma and die.

Study investigators emphasize that oral insulin cannot be used to treat existing diabetes because it is digested by the body. However, they theorize that giving people insulin capsules or injections before they develop the disease may stop the body's immune system from destroying insulin-producing cells.

UT Southwestern is one of 10 clinics and 350 recruitment sites participating in the DPT-1. The study is sponsored by the NIDDK in cooperation with the National Institute of Child Health and Human Development, National Institute of Allergy and Infectious Diseases, National Center for Research Resources, Juvenile Diabetes Foundation International and American Diabetes Association.

For more information about participating in the study, call (214) 640-5974.

UT Southwestern Medical Center

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.